Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma: A phase II International Oncology Study Group study

Cancer

Volumn 94, Issue 10, 2002, Pages 2645-2652

  Mohrbacher, Ann F ^a   Gregory, Stephanie A ^b   Gabriel, Don A ^c   Rusk, Jason M ^d   Giles, Francis J ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d GILEAD SCIENCES   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Hematologic malignancy; Liposomal daunorubicin; Multiple myeloma; Recurrence

Indexed keywords

ALLOPURINOL; DAUNORUBICIN; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DEHYDRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; DAUNORUBICIN; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 0037094106     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10561     Document Type: Article

References (72)

1. Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma
2. Multiple myeloma and other differentiated B-cell disorders
3. Current therapy of refractory multiple myeloma
4. Salvage therapy for multiple myeloma: The University of Arkansas experience
5. Long-term follow-up after high-dose therapy for high-risk multiple myeloma
6. Total therapy with tandem transplants for newly diagnosed multiple myeloma
7. Recent advances in the treatment of multiple myeloma
8. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
9. Early myeloablative therapy for multiple myeloma
10. Limited value of myeloablative therapy for late multiple myeloma
11. The treatment of multiple myeloma
12. Effective treatment of advanced multiple myeloma refractory to alkylating agents
13. VAD chemotherapy - Toxicity and efficacy - In patients with multiple myeloma and other lymphoid malignancies
14. VAD chemotherapy as remission induction for multiple myeloma
15. Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma
16. Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and Adriamycin in continuous infusion
17. VAD or VMBCP in severe multiple myeloma
18. VAD chemotherapy for refractory multiple myeloma
19. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma
20. VAD-based regimens as primary treatment for multiple myeloma
21. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma
22. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma
23. Infused vincristine and Adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients
24. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma
25. A Phase I/II trial of Z-Dex (oral idarubicin and dexamethasone) an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma
26. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study
27. VAD regimen in the treatment of resistant multiple myeloma: Slow or fast infusion?
28. Cyclophosphamide, etoposide, vincristine, Adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An International Oncology Study Group (IOSG) Phase II protocol
29. Refractory multiple myeloma: Recent advances in therapy
30. Adriamycin cardiotoxicity in man
31. The cardiotoxicity of anticancer agents
32. Structural requirements for anthracycline-induced cardiotoxicity and antitumor effects
33. Anthracycline-induced cardiotoxicity in children with malignancies
34. The long-term complications of chemotherapy in childhood genitourinary tumors
35. The biochemistry of P-glycoprotein-mediated multidrug resistance
36. Clinical modulation of multidrug resistance in multiple myeloma: Effect of cyclosporine on resistant tumor cells
37. VAD-cyclosporine therapy for VAD-resistant multiple myeloma
38. Drug resistance in multiple myeloma
39. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome)
40. Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM
41. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance
42. Liposomal daunorubicin: In vitro and in vivo efficacy in multiple myeloma
43. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells
44. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: Clinical and pharmacokinetic outcomes
45. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes
46. Liposomal daunorubicin in advanced Kaposi's sarcoma: A Phase II study
47. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue
48. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin
49. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma
50. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma
51. A Phase II study of DaunoXome in advanced urothelial transitional cell carcinoma
52. Phase I study of liposomal daunorubicin in patients with acute leukemia
53. Liposome encapsulated daunorubicin (daunoxome) for acute leukemia
54. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: Implications for liposome-encapsulated daunorubicin
55. Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance
56. Multiple myeloma and Kaposi's sarcoma: What is the association?
57. Multiple myeloma associated with Kaposi sarcoma
58. Kaposi's sarcoma associated with multiple myeloma. Report of a patient and review of the literature
59. Kaposi's sarcoma in patient with multiple myeloma, sideroblastic anaemia, and T-lymphocyte abnormalities
60. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
61. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma
62. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma
63. A review of angiogenesis and anti-angiogenic therapy with thalidomide in multiple myeloma
64. Bone marrow microvessel density is a prognostic factor for survival in multiple myeloma and a significant decrease in microvessel density occurs in patients who achieve a remission after chemotherapy
65. Thalidomide plus dexamethasone (THAL/DEX) and thalidomide alone (THAL) as first line therapy for newly diagnosed myeloma (MM)
66. Thalidomide with dexamethasone for resistant multiple myeloma
67. Low-dose of thalidomide in the treatment of refractory myeloma
68. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
69. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
70. Treatment of myeloma
71. Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma
72. A Phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma